수정된 비봉합사 커프 기술을 사용한 뮤린 자궁 경부 대동맥 이식 모델

Executive Industry Relevance

Chronic allograft vasculopathy (CAV) remains a leading cause of long-term graft failure in solid organ transplantation, with limited therapeutic options due to incomplete understanding of its pathophysiology. This murine cervical aortic transplantation model using a modified non-suture cuff technique provides a reproducible, minimally microsurgical platform to study CAV mechanisms and evaluate potential interventions. By enabling consistent vascular anastomosis and controlled warm ischemic time, the model supports preclinical de-risking of therapeutic strategies targeting vascular remodeling in transplantation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses in vascular pathology by modeling human-relevant neointimal hyperplasia and luminal narrowing in allografted aortas.
• Operational Value: Offers a standardized, suture-free anastomosis that reduces technical variability and supports high success rates across experimental groups.
• Predictive Value: Facilitates biological de-risking of targets involved in smooth muscle cell-mediated vascular remodeling, as demonstrated by SM22-positive neointima formation.

Screening & Assay Development

• Scientific Value: Provides a quantifiable output—neointimal hyperplasia and luminal stenosis—enabling dose-response assessment of candidate compounds in a disease-relevant system.
• Operational Value: Ensures assay readiness through constant cuff diameter and standardized surgical timing, minimizing anastomosis-related confounding variables.
• Translational Value: Supports screening readiness by using fully MHC-mismatched allografts to mimic human alloimmune responses in vascular graft failure.

Translational & Preclinical Research

• Scientific Value: Models chronic allograft vasculopathy as a progressive pathology, allowing longitudinal assessment of graft changes up to 28 days post-transplant.
• Operational Value: Enables histological and immunofluorescence analysis (e.g., Van-Gieson’s staining, SM22 detection) to validate target engagement and mechanism of action.
• Predictive Value: Supports risk-adjusted advancement decisions by distinguishing between syngeneic (minimal hyperplasia) and allogeneic (significant hyperplasia) graft responses.

Pipeline & Workflow Integration

The model fits within the discovery continuum from target validation through preclinical evaluation, particularly for therapies aimed at inhibiting vascular smooth muscle proliferation or modulating immune-mediated vascular injury in transplantation.

• Discovery Biology: Supports hypothesis testing on pathways driving neointima formation, enabling mechanistic de-risking before lead optimization.
• Screening: Delivers reproducible, quantitative vascular outcomes suitable for compound library screening in a standardized surgical model.
• Analytics: Generates measurable endpoints—luminal area, neointimal thickness, smooth muscle marker expression—enabling comparative analysis across treatment groups.
• Translational Research: Mirrors human CAV pathophysiology, supporting continuity from discovery to preclinical validation of vascular-protective agents.
• Enterprise Reuse: Establishes a reusable surgical platform for multiple therapeutic modalities (small molecules, biologics, gene therapies) targeting vascular remodeling in transplant settings.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence in target validation by modeling a clinically relevant cause of late graft loss with defined histological and functional readouts.
• Operational Value: Improves reproducibility and reduces inter-animal variability through standardized non-suture cuff technique and controlled operative conditions.
• Strategic Value: Informs go/no-go decisions by providing early evidence of efficacy in preventing pathological vascular remodeling, reducing late-stage failure risk.
• Portfolio Impact: Enables risk-stratified prioritization of vascular-targeted candidates based on their ability to suppress neointimal hyperplasia in an immunocompetent allograft model.

Implementation Considerations

• Requires expertise in microsurgical techniques, including vessel isolation, ligation, and inversion using fine forceps and micro scissors.
• Depends on specialized instrumentation such as vascular dilatators, heparinized saline flush systems, and stereomicroscopes for precise anastomosis.
• Necessitates standardized postoperative care and timed sacrifice (e.g., 28 days) to ensure consistent assessment of chronic vasculopathy development.
• Involves adaptation considerations when extending to different mouse strains or graft sizes, though cuff dimensions help maintain anastomotic consistency.
• Limited to modeling arterial vasculopathy; venous thrombosis or cardiac-specific pathologies require complementary models.

Biopharma FAQs